Enhanced Corneal Endothelial Disease Treatment System

The present inventive concept relates to novel improvements and enhancements to the original composition or method for treating or preventing corneal endothelial diseases using (T)EW-7197, providing better efficacy, safety, and patient outcomes.

The original patent disclosed a composition or method for treating or preventing corneal endothelial diseases using (T)EW-7197. However, there remained limitations in terms of efficacy, safety, and patient outcomes. The present inventive concept addresses these limitations by providing direct improvements and enhancements to the original invention, resulting in better treatment outcomes for patients.

The present inventive concept encompasses a system for treating or preventing corneal endothelial diseases, comprising a topical formulation of (T)EW-7197 and a corneal endothelial cell-targeting moiety, which enhances corneal endothelial cell migration and proliferation. Additionally, the inventive concept includes a method for enhancing the efficacy of (T)EW-7197 by co-administering it with a Rho-kinase inhibitor, a pharmaceutical composition forming a sustained-release matrix, a method for reducing the incidence of corneal endothelial disease recurrence, and a kit for treating or preventing corneal endothelial diseases.

The present inventive concept's novelty lies in the combination of (T)EW-7197 with a corneal endothelial cell-targeting moiety, the co-administration with a Rho-kinase inhibitor, the sustained-release matrix composition, and the corneal endothelial cell-based therapy. These combinations and enhancements provide a non-obvious solution to the limitations of the original patent, resulting in improved treatment outcomes.

Alternative embodiments of the inventive concept may include varying the type of corneal endothelial cell-targeting moiety, the specific Rho-kinase inhibitor used, the composition of the sustained-release matrix, or the specific corneal endothelial cell-based therapy employed. These variations can be used to tailor the treatment to specific patient needs or disease types.

The present inventive concept has significant commercial potential in the ophthalmology market, particularly in the treatment of corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy and corneal guttata. The improved efficacy, safety, and patient outcomes offered by the inventive concept can lead to increased adoption and market share.